Synonyms: Iscover® | Plavix® | SR-25990C
clopidogrel is an approved drug (FDA (1997), EMA (1998))
Compound class:
Synthetic organic
Comment: Clopidogrel is a prodrug converted by liver CYP450 via 2-oxo-clopidogrel to an active metabolite, listed in GtoPdb as clopidogrel (active metabolite) [2]. Marketed formulations may contain clopidogrel bisulfate (PubChem CID 115366).
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖View more information in the IUPHAR Pharmacology Education Project: clopidogrel |
|
No information available. |
Summary of Clinical Use |
Clopidogrel is used for its anti-clotting action in patients with conditions such as acute coronary syndrome, myocardial infarction, peripheral vascular diseases and stroke. |
Mechanism Of Action and Pharmacodynamic Effects |
Clopidogrel prevents adenosine diphosphate (ADP) from binding to platelet membrane P2Y12 receptors (P2RY12). This receptor plays a role in platelet aggregation and thrombus formation [1], thus its inhibition reduces the risk of thrombus formation. |
External links |
For extended ADME data see the following: Drugs.com European Medicines Agency (EMA) |